NasdaqGS - Nasdaq Real Time Price USD

United Therapeutics Corporation (UTHR)

Compare
363.36 -0.19 (-0.05%)
As of 9:57 AM EDT. Market Open.
Loading Chart for UTHR
DELL
  • Previous Close 363.55
  • Open 362.37
  • Bid 361.29 x 100
  • Ask 365.56 x 100
  • Day's Range 360.32 - 366.08
  • 52 Week Range 208.62 - 366.08
  • Volume 43,939
  • Avg. Volume 538,891
  • Market Cap (intraday) 16.166B
  • Beta (5Y Monthly) 0.57
  • PE Ratio (TTM) 16.68
  • EPS (TTM) 21.78
  • Earnings Date Oct 30, 2024 - Nov 4, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 357.77

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

www.unither.com

1,168

Full Time Employees

December 31

Fiscal Year Ends

Recent News: UTHR

View More

Performance Overview: UTHR

Trailing total returns as of 9/3/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

UTHR
65.24%
S&P 500
17.31%

1-Year Return

UTHR
59.33%
S&P 500
23.91%

3-Year Return

UTHR
71.14%
S&P 500
23.33%

5-Year Return

UTHR
340.11%
S&P 500
91.21%

Compare To: UTHR

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: UTHR

View More

Valuation Measures

Annual
As of 8/30/2024
  • Market Cap

    16.17B

  • Enterprise Value

    13.70B

  • Trailing P/E

    16.71

  • Forward P/E

    14.49

  • PEG Ratio (5yr expected)

    1.67

  • Price/Sales (ttm)

    6.84

  • Price/Book (mrq)

    2.84

  • Enterprise Value/Revenue

    5.24

  • Enterprise Value/EBITDA

    9.03

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    40.87%

  • Return on Assets (ttm)

    11.79%

  • Return on Equity (ttm)

    19.25%

  • Revenue (ttm)

    2.62B

  • Net Income Avi to Common (ttm)

    1.07B

  • Diluted EPS (ttm)

    21.78

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.97B

  • Total Debt/Equity (mrq)

    8.78%

  • Levered Free Cash Flow (ttm)

    649.9M

Research Analysis: UTHR

View More

Company Insights: UTHR

Research Reports: UTHR

View More

People Also Watch